Xcell Therapeutics Hits Upper Limit...Celemics·QuadMedicine ↑[K-Bio Pulse] 김승권 2026.02.06 오전 08:00 Celemics hits limit before after hours filing[K-Bio Pulse] 나은경 2026.02.04 오전 08:00 Investor Sentiment Lifted by Expectations of ‘Tangible Results’ Ensol Bio & L&K BioMed Surge[K-... 한광범 2026.01.26 오전 08:00 Samsung Biologics Acquires GSK Manufacturing Facility, Establishing First U.S. Production Hub 한광범 2025.12.22 오전 08:13 Samsung Biologics to split off biosimilar business 임정요 2025.05.22 오후 04:06 A Pharmaceutical Company That Rose Through Diversification While Others Focused on a Single Field 류성 2025.09.02 오후 08:00 L&K BIOMED, 51% Increase Operating Profit YoY…Turns to Net Profit Black 김진수 2025.02.26 오후 01:25 Celltrion completes acquisition of Lilly’s U.S. plant, launches $470m CMO business 송영두 2026.01.02 오전 08:03 Syntekabio wins SI deal from HYBE’s Weverse unit 나은경 2025.12.17 오후 01:42 Oncocross Soars on Diversification Hopes, ABL Bio Slides on Trial Data[K-Bio Pulse] 송영두 2025.04.03 오전 08:08 더 보기 로딩중..
Diversification
Diversification
![Xcell Therapeutics Hits Upper Limit...Celemics·QuadMedicine ↑[K-Bio Pulse]](https://image.edaily.co.kr/images/vision/files/NP/S/2026/02/PS26020600366b.jpg)
![Celemics hits limit before after hours filing[K-Bio Pulse]](https://image.edaily.co.kr/images/vision/files/NP/S/2026/02/PS26020400292b.jpg)
![Oncocross Soars on Diversification Hopes, ABL Bio Slides on Trial Data[K-Bio Pulse]](https://image.edaily.co.kr/images/vision/files/NP/S/2025/04/PS25040300289b.jpg)